Categories

You can filter the research news archive by selecting one or multiple categories from the following list.






















  Show all news

 

23 November 2018

Lessons about Testosterone Therapy from the Testosterone Trials

Lessons about Testosterone Therapy from the Testosterone Trials

The Testosterone Trials show that testosterone therapy confers significant and clinically meaningful health benefits in older men with low testosterone levels. Even though the Testosterone Trials aimed to recruit men with hypogonadism due to no apparent reason other than age, in fact the majority of enrolled men were obese and more than one third had type 2 diabetes. Obesity, metabolic syndrome and/or type 2 diabetes are stronger risk factors for hypogonadism than aging per se. Consequently, the Testosterone Trials provide compelling evidence that testosterone therapy confers significant benefits in the growing population of men with obesity and/or type 2 diabetes. Furthermore, the Testosterone Trials confirm the safety in this patient population; the placebo group experienced more adverse events than the testosterone group.

An additional notable aspect of the Testosterone Trials is that they refute FDA’s position that testosterone therapy should only be given to men with classical hypogonadism (caused by pituitary injury/tumor, testicular damage or Klinefelter’s syndrome).


Last updated: 2019
G.MKT.GM.MH.02.2018.0506